- Hives treatment encompasses a wide range of therapeutic options designed to relieve symptoms such as itching, redness, and swelling caused by acute or chronic urticaria. Treatment approaches include oral antihistamines, H2 antagonists, and other medications, offering both immediate relief and long-term management, depending on the severity and underlying cause
- The rising demand for hives treatment is largely driven by increasing awareness of dermatological conditions, the growing prevalence of allergic reactions and autoimmune disorders, and the availability of effective over-the-counter and prescription medications. A surge in teledermatology platforms is also making treatment more accessible, particularly in remote and underserved areas
- North America dominates the hives treatment market with the largest revenue share of 38.4% in 2025, attributed to the high prevalence of chronic urticaria, advanced healthcare infrastructure, and a strong presence of pharmaceutical leaders focusing on dermatology. The U.S. leads regional growth due to continuous innovation in drug development and strong patient awareness initiatives
- Asia-Pacific is projected to be the fastest-growing region during the forecast period, fueled by a growing patient pool, increased access to healthcare, and rising healthcare expenditures across countries like India and China
- The oral segment is expected to dominate the hives treatment market with a market share of 57.6% in 2025, owing to its ease of administration, patient preference, and widespread availability of antihistamines and other supportive oral drugs in both prescription and non-prescription formats
